BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
-2.25%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$524M
AUM Growth
+$524M
(-11%)
Cap. Flow
-$50.9M
Cap. Flow
% of AUM
-9.7%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
2
Reduced
–
Closed
1
Top Buys
| 1 |
Lineage Cell Therapeutics
LCTX
|
$7.67M |
| 2 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
$2.53M |
Top Sells
| 1 |
CYNO
Cynosure, Inc. Class A
CYNO
|
$61.1M |
Sector Composition
| 1 | Healthcare | 46.73% |
| 2 | Consumer Staples | 42.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Monster Beverage
MNST
$60.9B
| $221M | 42.23% | 4,797,408 | – | – |
|
2
STAAR Surgical
STAA
$1.36B
| $106M | 20.28% | 10,855,179 | – | – |
|
|
3
Lineage Cell Therapeutics
LCTX
$267M
| $93.6M | 17.84% | 27,119,254 +2,222,222 | +9% | +$7.67M |
|
4
iShares Russell 2000 ETF
IWM
$67B
| $57.7M | 11.01% | 420,000 | – | – |
|
|
IMDX
5
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $18.2M | 3.47% | 3,056,680 +425,000 | +16% | +$2.53M |
|
|
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $14.4M | 2.74% | 322,411 | – | – |
|
|
AST
7
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $12.6M | 2.4% | 3,699,848 | – | – |
|
|
AST.WS
8
DELISTED
Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
| $140K | 0.03% | 328,205 | – | – |
|
|
CYNO
9
DELISTED
Cynosure, Inc. Class A
CYNO
| – | – | -1,338,827 | Closed | -$61.1M |
|